annual meeting program - American Society of Clinical Oncology

Sunday, June 6, 2010
Brd. 2D Panitumumab (pmab) with FOLFIRI as first-line treatment of patients (pts)
with metastatic colorectal cancer (mCRC): Resections and curative surgery
in a phase II single arm, multicenter study (20060314). (Abstract #3545)
R. Hofheinz, L. Mineur, R. Greil, C. Kohne, H. Letocha, J. Thaler, E. Fernebro,
E. Gamelin, L. DeCosta, M. Karthaus, 20060314 Study Group
Brd. 2E Surgical cytoreduction in patients with colorectal peritoneal carcinomatosis
treated with contemporary chemotherapy. (Abstract #3546)
V. G. Gava, D. L. Reidy, P. Paty, L. Saltz, K. Y. Chung, M. R. Weiser, L. K. Temple,
N. H. Segal, L. F. Moreira, G. Nash, Colorectal Service, Memorial Sloan-Kettering
Cancer Center
Brd. 2F Outcome of 123 patients (pts) with peritoneal carcinomatosis (PC)—Limited
metastases from colorectal cancer (CRC) and appendiceal adenocarcinoma
(ADC): The British Columbia Cancer Agency (BCCA) experience. (Abstract
#3547)
F. Aubin, S. Gill, C. Speers, H. F. Kennecke
Brd. 2G Outcome of colorectal liver metastases vanishing under chemotherapy and
finally missing after surgery. (Abstract #3548)
S. Gaujoux, D. Goéré, P. Misitano, P. Burtin, F. Dumont, V. Boige, D. Malka,
C. Dromain, M. Ducreux, D. Elias
Brd. 2H Dual VEGF inhibition with sorafenib and bevacizumab (BEV) as salvage
therapy in metastatic colorectal cancer (mCRC): Results of the phase II
North Central Cancer Treatment Group study N054C. (Abstract #3549)
A. Grothey, J. M. Lafky, B. W. Morlan, P. J. Stella, S. R. Dakhil, P. D. Steen,
W. S. Loui, B. M. Bot, S. R. Alberts, J. T. Reynolds
Brd. 3A FEB study: Efficacy treatment evaluation in metastatic colorectal cancer
(mCRC) patients (pts) changing monoclonal antibody (MA) after progression
with chemotherapy. (Abstract #3550)
R. Grande, G. Cianci, I. Sperduti, D. Gemma, A. Gelibter, M. Giampaolo,
L. Mentuccia, F. Narducci, E. Magnolfi, T. Gamucci
Brd. 3B CPT-11/5-fluorouracil (5-FU)/leucovorin (FA)/oxaliplatin (L-OHP) (CPT-11-
FFL) plus cetuximab (Cmab) in unselected advanced colorectal cancer (ACC)
patients. (Abstract #3551)
C. Garufi, A. Torsello, C. Campanella, G. M. Ettorre, G. Vennarecci, E. Melucci,
M. Zeuli, I. Sperduti, A. Gelibter, F. Cognetti
Brd. 3C Metronomic therapy irinotecan (IRI) capecitabine (CAP) plus bevacizumab
(BEV) in treatment of advanced colorectal cancer (ACRC) in very elderly
people. (Abstract #3552)
I. U. Carreca, F. Bellomo, S. L. Burgio, G. Pernice, D. Piazza, L. Balducci
Brd. 3D Phase II trial alternating mFOLFOX 6 and FOLFIRI (FIREFOX) regimens in
first-line treatment of advanced colorectal cancer in Japanese patients
(KSCC 0701). (Abstract #3553)
Y. Akagi, S. Tokunaga, Y. Emi, Y. Kakeji, T. Kusumoto, H. Baba, Y. Ogata,
T. Tanaka, K. Shirouzu, Y. Maehara, Kyushu Study Group of Clinical Cancer
(KSCC)
Brd. 3E Analysis of prognostic factors for 60-day mortality: Evaluation of a
randomized phase III trial investigating FUFIRI versus mIROX as first-line
treatment of metastatic colorectal cancer (mCRC). (Abstract #3554)
C. Giessen, A. Schalhorn, S. Stintzing, V. Heinemann
Brd. 3F Capecitabine (C) and bevacizumab (B) for nonresectable metastatic
colorectal cancer (mCRC) patients: Results from phase II AIO 0105 trial.
(Abstract #3555)
A. Kretzschmar, D. M. Behringer, T. Wolff, J. Zimber, S. Hegewisch-Becker,
E. Kettner, K. Pflüger, A. Kirsch, N. Ziegenhagen, D. Arnold
257
SUNDAY